公开(公告)号：US11911475B2

公开(公告)日：2024-02-27

申请号：US17848967

申请日：2022-06-24

Applicant: SIRNA THERAPEUTICS, INC.

Inventor： Matthew G. Stanton ,  Brian W. Budzik ,  Gregory L. Beutner ,  Hongbiao Liao

IPC: A61K47/18 ,  C07C211/08 ,  C07C211/04 ,  C07C211/17 ,  C07C211/21 ,  C12N15/88 ,  C07D207/06 ,  A61K48/00 ,  A61K45/00

CPC classification number: A61K47/18 ,  C07C211/04 ,  C07C211/08 ,  C07C211/17 ,  C07C211/21 ,  C07D207/06 ,  C12N15/88 ,  A61K45/00 ,  A61K48/00

Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

公开(公告)号：US09890108B2

公开(公告)日：2018-02-13

申请号：US15034135

申请日：2014-10-15

Applicant: Renat Kadyrov

Inventor： Renat Kadyrov

IPC: C07C209/52 ,  C07B43/04 ,  C07C209/68 ,  C07C213/00 ,  C07C253/30 ,  C07D295/023 ,  C07D295/027 ,  C07D295/03 ,  C07C213/02

CPC classification number: C07C209/52 ,  C07B43/04 ,  C07C209/68 ,  C07C213/00 ,  C07C213/02 ,  C07C253/30 ,  C07C2601/14 ,  C07D295/023 ,  C07D295/027 ,  C07D295/03 ,  C07C211/04 ,  C07C211/08 ,  C07C215/08 ,  C07C211/48 ,  C07C211/07 ,  C07C211/27 ,  C07C255/30

Abstract: The present invention relates to a process for the preparation of amines, comprising the following steps: Reaction of a (i) amide acetal of the general formula (I), or (ii) ketene N,O-acetal of the general formula (II), or (iii) ester imide of the general formula (III) with H2 in the presence of a hydrogenation catalyst, where catalyst and amide acetal or ketene N,O-acetal or ester imide are used in a molar ratio of from 1:10 to 1:100 000 and where a hydrogen pressure of from 0.1 bar to 200 bar is established and where a temperature in the range of from 0° C. to 250° C. is established.

公开(公告)号：US09550177B2

公开(公告)日：2017-01-24

申请号：US14645626

申请日：2015-03-12

Applicant: Tracy Margaret Davis ,  Joel Schmidt ,  Dan Xie

Inventor： Tracy Margaret Davis ,  Joel Schmidt ,  Dan Xie

IPC: B01D53/56 ,  B01J29/74 ,  B01D53/94 ,  B01J29/70 ,  C07C209/16 ,  C07C1/20 ,  B01J20/18 ,  B01J29/76 ,  B01D53/22 ,  C01B39/48 ,  B01D53/02

CPC classification number: B01J29/74 ,  B01D53/02 ,  B01D53/228 ,  B01D53/9413 ,  B01D53/945 ,  B01D53/9486 ,  B01D2255/50 ,  B01D2256/245 ,  B01D2257/504 ,  B01D2258/01 ,  B01J20/18 ,  B01J29/70 ,  B01J29/7049 ,  B01J29/76 ,  B01J35/002 ,  B01J35/1038 ,  C01B39/48 ,  C07C1/20 ,  C07C209/16 ,  C07C2529/70 ,  Y02A50/2324 ,  Y02C10/08 ,  Y02C10/10 ,  Y02P20/152 ,  Y02P20/52 ,  Y02P30/42 ,  Y02T10/22 ,  C07C211/04 ,  C07C11/04 ,  C07C11/06 ,  C07C11/08

Abstract: This disclosure is directed to uses for a new crystalline molecular sieve designated SSZ-101. SSZ-101 is synthesized using a N-cyclohexylmethyl-N-ethylpiperidinium cation as a structure directing agent.

Abstract translation: 本公开涉及用于称为SSZ-101的新结晶分子筛的用途。 使用N-环己基甲基-N-乙基哌啶鎓阳离子作为结构导向剂合成SSZ-101。

公开(公告)号：US20160340197A1

公开(公告)日：2016-11-24

申请号：US15098450

申请日：2016-04-14

Applicant: Chevron U.S.A. Inc.

Inventor： Stacey Ian Zones ,  Dan Xie ,  Robert James Saxton

IPC: C01B39/46 ,  C07C209/16 ,  B01J29/06 ,  C07C1/24 ,  B01D53/94 ,  B01J29/70

CPC classification number: C01B39/46 ,  B01D53/228 ,  B01D53/9413 ,  B01D53/9486 ,  B01D2253/108 ,  B01D2255/50 ,  B01D2256/245 ,  B01D2257/404 ,  B01D2257/504 ,  B01D2257/702 ,  B01J29/061 ,  B01J29/70 ,  B01J29/72 ,  B01J29/78 ,  C01B39/48 ,  C07C1/20 ,  C07C1/24 ,  C07C209/16 ,  C07C2529/70 ,  C07C2529/72 ,  Y02C10/10 ,  Y02P20/152 ,  Y02P20/52 ,  Y02P30/42 ,  C07C11/04 ,  C07C11/06 ,  C07C11/08 ,  C07C211/04

Abstract: Uses for a new crystalline molecular sieve designated SSZ-27 are disclosed. SSZ-27 is synthesized using a hexamethyl [4.3.3.0] propellane-8,11-diammonium cation as a structure directing agent.

Abstract translation: 公开了一种称为SSZ-27的新结晶分子筛的用途。 使用六甲基[4.3.3.0]推进剂-8,11-二铵阳离子作为结构导向剂合成SSZ-27。

公开(公告)号：US20150353367A1

公开(公告)日：2015-12-10

申请号：US14626779

申请日：2015-02-19

Applicant: Stacey Ian ZONES ,  Dan XIE ,  Cong-Yan CHEN ,  Ann Jia-Bao LIANG

Inventor： Stacey Ian ZONES ,  Dan XIE ,  Cong-Yan CHEN ,  Ann Jia-Bao LIANG

IPC: C01B39/48 ,  B01D53/94 ,  B01J29/70 ,  B01D71/02 ,  C07C1/20 ,  C07C209/16 ,  B01D53/22 ,  B01D53/02 ,  B01J20/18

CPC classification number: B01J29/70 ,  B01D53/02 ,  B01D53/228 ,  B01D53/9413 ,  B01D53/945 ,  B01D53/9486 ,  B01D71/024 ,  B01D71/025 ,  B01D2253/108 ,  B01D2253/116 ,  B01D2255/1021 ,  B01D2255/1023 ,  B01D2255/1025 ,  B01D2255/2063 ,  B01D2255/2073 ,  B01D2255/20738 ,  B01D2255/20746 ,  B01D2255/20753 ,  B01D2255/20761 ,  B01D2255/20784 ,  B01D2255/20792 ,  B01D2255/50 ,  B01J20/18 ,  C01B39/48 ,  C07C1/20 ,  C07C209/16 ,  C07C2529/70 ,  Y02A50/2324 ,  Y02P20/52 ,  Y02P30/42 ,  Y02T10/22 ,  C07C211/04 ,  C07C11/04 ,  C07C11/06 ,  C07C11/08

Abstract: This disclosure is directed to uses for a new crystalline molecular sieve designated SSZ-99. SSZ-99 is synthesized using a methylethyldiisopropylammonium cation as a structure directing agent.

Abstract translation: 本公开涉及用于称为SSZ-99的新型结晶分子筛的用途。 使用甲基乙基二异丙基铵阳离子作为结构导向剂合成SSZ-99。

公开(公告)号：US09180444B2

公开(公告)日：2015-11-10

申请号：US14433500

申请日：2013-10-11

Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.

Inventor： Toshihiro Nomura ,  Katsumi Higuchi ,  Akio Hashimoto ,  Sachiko Arie

IPC: B01J37/10 ,  B01J37/08 ,  B01J29/85 ,  C07C209/16 ,  C07C209/64

CPC classification number: B01J37/10 ,  B01J29/85 ,  B01J35/023 ,  B01J37/0063 ,  B01J37/08 ,  B01J2229/186 ,  B01J2229/36 ,  B01J2229/40 ,  C07C209/16 ,  C07C209/64 ,  C07C211/04

Abstract: According to the present invention, a method for producing a catalyst for use in the production of a methylamine compound can be provided, wherein the catalyst comprises a modified crystalline silicoaluminophosphate salt molecular sieve. The method comprises: a moisture control step of adsorbing moisture onto a crystalline silicoaluminophosphate salt molecular sieve in an amount of 5 to 30 wt % of the crystalline silicoaluminophosphate salt molecular sieve; and a step of heating the crystalline silicoaluminophosphate salt molecular sieve having moisture adsorbed thereon under a pressure of 0.1 MPa or more and at a temperature of 130 to 350° C. for 5 to 40 hours.

Abstract translation: 根据本发明，可以提供用于生产甲胺化合物的催化剂的制备方法，其中催化剂包含改性的结晶硅铝磷酸盐分子筛。 该方法包括：以结晶硅铝磷酸盐分子筛的5〜30重量％的量将水分吸附在结晶硅铝磷酸盐分子筛上的湿度控制步骤; 以及在0.1MPa以上的压力和130〜350℃的温度下加热吸附有水分的结晶硅铝磷酸盐分子筛5〜40小时的工序。

公开(公告)号：US20150307528A1

公开(公告)日：2015-10-29

申请号：US13514464

申请日：2010-10-25

Applicant: Wei Wang ,  Shuguang Zhou ,  Long Qin ,  Bufan Ren ,  Zhigang Qian ,  Tao Liu ,  Huiling She ,  Yaxian Zhang

Inventor： Wei Wang ,  Shuguang Zhou ,  Long Qin ,  Bufan Ren ,  Zhigang Qian ,  Tao Liu ,  Huiling She ,  Yaxian Zhang

IPC: C07F9/38 ,  A01N57/20 ,  A01N33/04 ,  C07C211/04

CPC classification number: C07F9/38 ,  A01N33/04 ,  A01N57/20 ,  C07B2200/13 ,  C07C211/04 ,  C07F9/3808 ,  A01N25/12

Abstract: This invention provides the herbicidal active ingredient, a dimethylamine salt crystal of N-phosphonomethyl glycine (glyphosate), its preparation process and a solid formulation containing the crystalline dimethylamine salt of glyphosate as well as its application. Said preparation process comprises adding glyphosate and a suitable amount of solvent into a conventional reactor and introducing a dimethylamine gas for reaction, wherein the reaction temperature is controlled between 5 and 90° C. After the completion of the reaction, the temperature is reduced slowly to a certain value, a crystalline dimethylamine salt of glyphosate is precipitated (or precipitated after a crystal seed is added).

Abstract translation: 本发明提供除草活性成分，N-膦酰基乙基甘氨酸（草甘膦）的二甲胺盐结晶，其制备方法和含有草甘膦结晶二甲胺盐的固体制剂及其应用。 所述制备方法包括将草甘膦和适量的溶剂加入到常规反应器中并引入二甲胺气体进行反应，其中反应温度控制在5至90℃之间。反应完成后，将温度缓慢降低至 一定值，草甘膦的结晶二甲胺盐沉淀（或在加入晶种后沉淀）。

公开(公告)号：US20150218142A1

公开(公告)日：2015-08-06

申请号：US14365802

申请日：2012-12-14

Applicant: GlaxoSmithKline LLC

Inventor： Mark Andrew Hatcher ,  Brian Alvin Johns ,  Michael Tolar Martin ,  Elie Amine Tabet ,  Jun Tang

IPC: C07D413/06 ,  A61K31/225 ,  C07C211/04 ,  C07C211/38 ,  C07C211/10 ,  C07C233/33 ,  C07C215/08 ,  C07C217/26 ,  A61K31/506 ,  C07D217/04 ,  A61K31/472 ,  A61K31/495 ,  C07D207/09 ,  A61K31/40 ,  C07D265/32 ,  A61K31/5375 ,  C07D213/40 ,  A61K31/44 ,  C07D265/30 ,  A61K31/54 ,  A61K31/551 ,  C07D205/04 ,  A61K31/397 ,  A61K45/06 ,  C07C219/06

CPC classification number: A61K31/568 ,  A61K31/222 ,  A61K31/225 ,  A61K31/397 ,  A61K31/40 ,  A61K31/44 ,  A61K31/472 ,  A61K31/495 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/54 ,  A61K31/551 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07C69/34 ,  C07C211/04 ,  C07C211/10 ,  C07C211/38 ,  C07C215/08 ,  C07C217/26 ,  C07C219/06 ,  C07C219/24 ,  C07C225/14 ,  C07C233/33 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2603/52 ,  C07D205/04 ,  C07D207/09 ,  C07D213/40 ,  C07D217/04 ,  C07D239/26 ,  C07D239/48 ,  C07D243/08 ,  C07D265/30 ,  C07D265/32 ,  C07D413/06 ,  C07D498/14 ,  C07J53/002 ,  C07J63/008

Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

Abstract translation: 本发明涉及具有下式I结构的化合物或其药学上可接受的盐。 本发明的化合物可用于治疗或预防HIV。

公开(公告)号：US20150011755A1

公开(公告)日：2015-01-08

申请号：US14375013

申请日：2013-02-06

Applicant: DR. REDDYS LABORATORIES LIMITED

Inventor： Mark P Jackson

IPC: C07C67/475 ,  C07C69/732 ,  C07D311/94 ,  C07C211/07 ,  C07C211/03 ,  C07D295/027 ,  C07C211/09 ,  C07C211/35 ,  C07C211/06 ,  C07C211/04 ,  C07C69/736 ,  C07C211/05

CPC classification number: C07C67/475 ,  C07C69/732 ,  C07C69/736 ,  C07C211/03 ,  C07C211/04 ,  C07C211/05 ,  C07C211/06 ,  C07C211/07 ,  C07C211/09 ,  C07C211/11 ,  C07C211/27 ,  C07C211/35 ,  C07C405/00 ,  C07C2601/08 ,  C07C2601/14 ,  C07D295/027 ,  C07D311/94

Abstract: The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Abstract translation: 本申请涉及前列腺素类似物的胺盐及其用于制备基本上纯的前列腺素类似物的用途。 具体实施方案涉及他氟前列素的胺盐及其用于制备基本上纯的他氟前列素的用途。

公开(公告)号：US20090088591A1

公开(公告)日：2009-04-02

申请号：US12258563

申请日：2008-10-27

Applicant: Marco Bosch ,  Roderich Roettger ,  Bernd Stein ,  Thomas Krug ,  Johann-Peter Melder ,  Theodor Weber

Inventor： Marco Bosch ,  Roderich Roettger ,  Bernd Stein ,  Thomas Krug ,  Johann-Peter Melder ,  Theodor Weber

IPC: C07C209/16

CPC classification number: C07C209/16 ,  B01J8/0221 ,  B01J8/0285 ,  B01J2208/00132 ,  B01J2208/00353 ,  B01J2208/0053 ,  C07C211/04

Abstract: In the continuous process for preparing alkylamines by reacting C1-4-alkanols with ammonia in the gas phase in the presence of a shape-selective fixed-bed catalyst in a cooled reactor, the shape-selective fixed-bed catalyst is present in a single contiguous fixed bed in the reactor and tubes through which coolants are passed run within the fixed bed to regulate the temperature of the fixed bed.

Abstract translation: 在冷却的反应器中，在形状选择性固定床催化剂存在下，在气相中使C 1-4 - 链烷醇与氨反应制备烷基胺的连续方法中，形状选择性固定床催化剂存在于单一 反应器中连续的固定床和冷却剂通过的管通过固定床内以调节固定床的温度。